August 2, 2023
12 p.m. ET
Duration: 30 minutes

Becker muscular dystrophy (BMD) is a serious dystrophinopathy. Declining function can begin at different ages, but once it begins, Becker patients are on an irreversible path to losing muscle and consequently, function.

For this second part of our series on Becker muscular dystrophy, we will discuss the following:

• The rationale for targeting fast muscle fibers in BMD.
• The use of blood biomarkers of muscle damage to give some perspective of muscle health in BMD
• The recent 12-month data from ARCH, an open label, single-center, Phase 1b study of EDG-5506 in adults with BMD.

Panelists

• Chair: John Wing, PhD, Sr Director Medical Affairs, Edgewise Therapeutics​
• Alan Russell, PhD, Chief Scientific Officer, Edgewise Therapeutics ​​
• Joanne Donovan, MD, PhD, Chief Medical Officer, Edgewise​ Therapeutics

If you have questions or comments, contact cdrummond@mdausa.org.
For more educational programs and resources, please visit. MDA Medical Education

This Industry Update Webinar is sponsored by Edgewise Therapeutics. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.